SFB 1054 Seminar - Rudi Beyaert
VIB-UGent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, Belgium
05.07.2018 at 12:15
Title: MALT1 in immune homeostasis and disease: from biology to therapy
MALT1 is a signaling protein that plays a key role in innate and adaptive immunity as well as in certain malignancies. In particular, MALT1 is essential for nuclear factor κB (NF-κB) activation downstream of T and B cell receptors, and supports T/B-cell activation and proliferation. In addition, MALT1 plays a role in the activation of other immune and non-immune cells. MALT1 hyperactivation is associated with autoimmunity and specific subtypes of B-cell lymphoma. For a long time, MALT1 was believed to function solely as a scaffold protein, providing a platform for the assembly of other NF-κB signaling proteins. However, this view changed dramatically when we and others found that MALT1 also has proteolytic activity that further fine-tunes signaling. MALT1 proteolytic activity is essential for T-cell activation and lymphomagenesis, suggesting that MALT1 is a promising therapeutic target for the treatment of autoimmunity and cancer. However, MALT1 is also involved in the development of natural Treg cells that keep the immune response in check, illustrating a potential risk of therapeutic targeting of MALT1 in the context of autoimmunity. I will present our recent work on MALT1-mediated signaling in different cell types, its role in immunity and inflammation, and possible implications for therapeutic targeting.
Venue:
BioMedical Center (BMC), Room N 01.017,
Großhaderner Str. 9, Planegg-Martinsried
Host: Daniel Krappmann (A04)
